Affordable Access

Publisher Website

Implementation of an ISO15189 accredited next-generation sequencing service with the fully automated Ion Torrent Genexus: the experience of a clinical diagnostic laboratory.

Authors
  • Werner, Réiltín1, 2
  • Connolly, Amy3
  • Bennett, Michael3
  • Hand, Collette K2
  • Burke, Louise3, 2
  • 1 Pathology Department, Cork University Hospital, Cork, Ireland [email protected]. , (Ireland)
  • 2 Department of Pathology, School of Medicine, University College Cork, Cork, Ireland. , (Ireland)
  • 3 Pathology Department, Cork University Hospital, Cork, Ireland. , (Ireland)
Type
Published Article
Journal
Journal of Clinical Pathology
Publisher
BMJ
Publication Date
Mar 20, 2024
Volume
77
Issue
4
Pages
278–283
Identifiers
DOI: 10.1136/jcp-2022-208625
PMID: 36522176
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Next-generation sequencing (NGS) is integral to the delivery of personalised medicine for targeted cancer therapy. Average turnaround times (TAT) from reference laboratories with advanced expertise in sequencing are typically 2-3 weeks. Prolonged TAT for biomarker analysis can adversely affect patient outcomes. The project aim was to establish an accredited NGS service integrated within a routine clinical diagnostic laboratory, in a designated tertiary cancer centre with no previous experience in NGS or bioinformatics. Platform selected was the novel Ion Torrent Genexus Sequencer with automated onboard library preparation, templating, sequencing and data analysis, with subsequent reporting using Oncomine Reporter software.Entire workflow validation was performed with a targeted panel, the Oncomine Precision Assay, on formalin-fixed paraffin embedded clinical tumour samples. Oncomine Reporter software was used to report on variants including mutations, copy number variations and fusions across 50 key genes.Samples included surgical resections, biopsies, cytology and commercial reference material. Assessment of criteria included analytical sensitivity, specificity, limit of detection, accuracy, repeatability and reproducibility, with the establishment of performance metrics and quality parameters. High sensitivity, specificity and reproducibility were achieved. DNA/RNA input requirements optimised to >10 ng, and sequencing performance established with a limit of detection of 5% when depth of coverage of 2500X was reached. This NGS service attained ISO15189 accreditation with no non-conformances and >56% reduction in TAT. Successful implementation, clinical validation and accreditation of a novel NGS technology was achieved in this institution, with a significantly improved TAT of results to oncologists. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Report this publication

Statistics

Seen <100 times